Tislelizumab Combined With Fruquintinib for Metastatic pMMR/MSS Colorectal Cancer

Summary

This is an open-label phase II study, with the aim of investigating the efficacy and safety of Tislelizumab + Fruquintinib combination therapy in ARID1A-mutated pMMR/MSS metastatic colorectal cancer who have been treated with standard chemotherapy that includes fluoropyrimidine, oxaliplatin, and irinotecan. Patients with hypermutated CRC that carries POLE/POLD1 mutations cannot be included.

Timeline

Start

2025-07

Primary completion

2025-07

Completion

2025-07

Drugs

Indications